NightHawk Biosciences (NHWK) has released an update to notify the public and investors about a regulation fd disclosure.
On January 30, 2024, the Company publicly announced its engagement in a Patent Agreement and the issuance of a Note. The press release provided with this announcement is not considered legally filed under the Securities Exchange Act or subject to its liabilities, nor will it be included in any future SEC filings made by the Company. The press release contains forward-looking statements protected under the Private Securities Litigation Reform Act.
For further insights into NHWK stock, check out TipRanks’ Stock Analysis page.
For a comprehensive understanding of the announcement, you can read the full document here.
